Stifel Reiterates Buy Rating on CTI BioPharma (CTIC), Expects Stock to Trade Up Substantially on Vonjo Approval
Tweet Send to a Friend
Stifel analyst Benjamin Burnett reiterated a Buy rating on CTI BioPharma (NASDAQ: CTIC), following approval of the company's Vonjo drug.The ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
